Mike Kelly has been appointed as President of US operations at Adapt Pharma. In this role, Kelly will have responsibility for all of the company's US operating activities.
Kelly brings nearly three decades of pharmaceutical experience, playing an instrumental role in the creation, development and strengthening of speciality brands and businesses for a number of pharmaceutical companies.
He joins Adapt Pharma from Covis Pharmaceuticals, where he was Chief Executive and a member of the board. Prior to this, he was a member of the founding management team of Azur Pharma and later, following a strategic merger, served as Senior Vice President of Sales and Marketing for Jazz Pharmaceuticals.
'I am delighted to welcome Mike to Adapt Pharma. He has established a highly successful track record in leadership roles in speciality pharmaceuticals,' said Seamus Mulligan, Chairman and Chief Executive of Adapt Pharma. 'His experience will be of great value as Adapt Pharma expands its commercial presence, starting with the launch of the Narcan (naloxone HCl) nasal spray.'
Narcan Nasal Spray is an opioid antagonist indicated for the emergency treatment of opioid overdose, as manifested by respiratory and/or central nervous system depression.
